PubRank

M Levrero

Author PubWeight™ 113.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999 5.33
2 Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994 4.42
3 The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998 3.70
4 Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997 3.54
5 Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990 3.04
6 Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997 2.74
7 Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998 2.40
8 In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J 1985 2.18
9 Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994 2.18
10 p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J 1997 2.05
11 Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996 1.96
12 Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol 1998 1.66
13 Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997 1.58
14 Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol Cell Biol 1994 1.56
15 Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. Hum Pathol 1997 1.48
16 The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci U S A 1997 1.46
17 Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994 1.42
18 Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem 2000 1.35
19 Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol 1996 1.35
20 Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999 1.31
21 Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J Biol Chem 1998 1.29
22 Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001 1.29
23 p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 2000 1.28
24 The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology 1998 1.27
25 Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem 1997 1.23
26 Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995 1.23
27 Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen. Virology 1989 1.21
28 Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun 1991 1.20
29 Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 1999 1.20
30 The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 1998 1.16
31 Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001 1.14
32 Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 1985 1.10
33 Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996 1.09
34 Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology. Hepatology 1998 1.09
35 Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 1998 1.07
36 DNp73alpha protects myogenic cells from apoptosis. Oncogene 2006 1.06
37 A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 2009 1.05
38 Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology 1993 1.04
39 Reactive oxygen intermediates mediate angiotensin II-induced c-Jun.c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem 1995 1.04
40 Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1983 1.04
41 Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tissue React 1993 1.04
42 T-cell subsets in the hyporesponsiveness to hepatitis B surface antigen (HBsAg) and antigen-specific suppressor lymphocytes in chronic hepatitis B virus (HBV) infection. Clin Immunol Immunopathol 1985 1.03
43 Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol 1994 1.03
44 The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. Oncogene 1993 0.99
45 Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. J Hepatol 1994 0.98
46 Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res 1998 0.98
47 Induction of gene expression via activator protein-1 in the ascorbate protection against UV-induced damage. Biochem J 2001 0.98
48 In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation. J Virol 1995 0.97
49 Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: a predictive index of liver histology severity. J Hepatol 1998 0.96
50 RelA/NF-kappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2007 0.93
51 Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol 1990 0.93
52 MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes. Oncogene 1997 0.92
53 Mitogen-activated kinase kinase kinase 1 regulates T cell receptor- and CD28-mediated signaling events which lead to NF-kappaB activation. Eur J Immunol 2000 0.92
54 Identification of a strong enhancer element upstream from the pregenomic RNA start site of the duck hepatitis B virus genome. J Virol 1991 0.91
55 Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation. Cancer Res 1998 0.91
56 Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J Gen Virol 2008 0.91
57 Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int J Cancer 1998 0.90
58 miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene 2012 0.89
59 Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. Virology 1992 0.88
60 Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. J Viral Hepat 1995 0.88
61 p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011 0.87
62 In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. Clin Exp Immunol 1987 0.85
63 Immunoregulatory T cells in HBV-induced chronic liver disease as defined by monoclonal antibodies. Clin Immunol Immunopathol 1983 0.84
64 Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype. FASEB J 2007 0.84
65 Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999 0.84
66 Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995 0.84
67 Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. Dig Liver Dis 2001 0.84
68 The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell Death Dis 2013 0.83
69 Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX. J Hepatol 1995 0.82
70 Binding of CDK9 to TRAF2. J Cell Biochem 1998 0.82
71 Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH). Liver 1986 0.82
72 Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol 1998 0.81
73 The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors. Arch Virol Suppl 1992 0.81
74 A temperature-conditional mutant of simian virus 40 large T antigen requires serum to inhibit myogenesis and does not induce DNA synthesis in myotubes. Cell Growth Differ 1997 0.81
75 Suppressor T cells role in the unresponsiveness to Candida albicans in chronic mucocutaneous candidiasis. Boll Ist Sieroter Milan 1985 0.81
76 Does the hepatitis C virus replicate in cells of the hematopoietic lineage? Hepatology 1998 0.81
77 Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. Dig Dis Sci 2001 0.80
78 HBeAg/anti-HBe system and development of primary hepatocellular carcinoma in patients with HBsAg-positive liver cirrhosis. Hepatogastroenterology 1983 0.80
79 Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. J Viral Hepat 2013 0.79
80 E1A stimulates FGF-2 release promoting differentiation of primary endothelial cells. Cell Death Differ 2000 0.78
81 The molecular basis of myocardial hypertrophy. Ann Ital Med Int 1994 0.78
82 Occult hepatitis B virus infection. Dig Liver Dis 2000 0.77
83 Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers. Arch Virol Suppl 1993 0.77
84 deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation. Cell Death Differ 2007 0.76
85 Chronic cryptogenic hepatitis in childhood is unrelated to hepatitis G virus. Pediatr Infect Dis J 1999 0.76
86 Truncated pre-S/S proteins transactivate multiple target sequences. Arch Virol Suppl 1992 0.76
87 Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. J Cell Biochem 1997 0.76
88 Peripheral blood mononuclear cells and regulatory T cells in acute viral hepatitis. Gut 1985 0.75
89 Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells. Ann N Y Acad Sci 1995 0.75
90 In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells. Immunology 1987 0.75
91 A second-generation hepatitis C virus confirmatory test for chronic hepatitis B virus infection. J Infect Dis 1992 0.75
92 Infection of circulating and liver infiltrating T cells by hepatitis C virus of different subtypes. Viral Immunol 1995 0.75
93 Antigen specific suppressor T cells from chronic hepatitis B virus (HBV) carriers inhibit the responsiveness to HBsAg of allogeneic high-responder lymphocytes. J Clin Lab Immunol 1985 0.75
94 Circulating HBsAg/IgM complexes in acute and chronic hepatitis B. Hepatogastroenterology 1984 0.75
95 Accumulation of a cellular protein bearing c-myc-like antigenicity in hepatic and non-hepatic delta antigen expressing cells. Arch Virol Suppl 1993 0.75
96 Clinical improvement and partial correction of the T cell defects of acquired immunodeficiency syndrome (AIDS) and lymphoadenopathy syndrome (LAS) by a calf thymus acid lysate. Eur J Cancer Clin Oncol 1986 0.75
97 Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. J Hepatol 1986 0.75
98 [The behavior of the HBeAg-anti-HBe system in chronic hepatitis]. Minerva Dietol Gastroenterol 1983 0.75
99 c-myc expression in cells infected with hepatitis delta virus. Prog Clin Biol Res 1993 0.75
100 The hepatitis B virus X gene product transactivates the HIV-LTR in vivo. Arch Virol Suppl 1993 0.75
101 The post-genomic era: workshop on chromatin immunoprecipitation-related techniques. Cell Death Differ 2007 0.75
102 Suppressor cell activity and T-cell subsets in multiple sclerosis. Acta Neurol (Napoli) 1987 0.75
103 Monitoring of NK-1 and NK-15 subsets and natural killer activity in kidney transplant recipients receiving cyclosporine. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985 0.75
104 A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat 2010 0.75
105 Recombinant immunoblot assay for hepatitis C virus antibody in chronic hepatitis. Arch Virol Suppl 1992 0.75
106 Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig Dis Sci 1999 0.75
107 Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors. Dig Liver Dis 2002 0.75
108 [Immunosuppressive therapy of chronic active hepatitis: results of a long-term follow-up]. Clin Ter 1983 0.75